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Introduction
Epigenetic modifications of histone tails, including acetylation and methylation, play an essential role in gene transcription (Bannister and Kouzarides, 2011; Gardner et al., 2011) . As such, epigenetic regulation serves key roles in the development, differentiation, maintenance and survival of diverse brain cells, hence impacting neuronal plasticity and memory (Grä ff and Tsai, 2013; Sweatt, 2013) . While epigenetic dysregulation is implicated in several neurodevelopmental, neuropsychiatric and neurodegenerative disorders, including Alzheimer's and Huntington's diseases (Grä ff et al., 2011; Dekker et al., 2014; Frost et al., 2014) , it is challenging to directly associate epigenetic (dys)regulation with specific neuronal or behavioural phenotypes.
To facilitate studies on the biological roles of chromatin modifications, genome modification technologies have been further developed to allow targeted overwriting of the epigenetic signature at endogenous loci, known as epigenetic editing (de Groote et al., 2012; Voigt and Reinberg, 2013; Stricker et al., 2017) . Programmable DNA binding platforms, including zinc finger proteins (ZFPs), transcription activation-like effectors (TALE), and more recently clustered regularly interspaced short palindromic repeats (CRISPR), have been exploited to induce locus-specific epigenetic editing by fusing these DNA binding domains targeting an endogenous locus to minimal effector domains of chromatin-modifying enzymes (Gaj et al., 2013) . Such epigenome editing tools (epi-editors) have been used to manipulate gene expression in several in vitro studies (Falahi et al., 2013; Konermann et al., 2013; Mendenhall et al., 2013; Chen et al., 2014; Hilton et al., 2015; CanoRodriguez et al., 2016) . Moreover, recent studies show that in vivo genome editing improves muscle function in mouse models of Duchenne muscular dystrophy (Long et al., 2016; Nelson et al., 2016; Tabebordbar et al., 2016) . So far, limited studies have investigated epigenetic editing in the CNS. Specifically, viral-mediated delivery of six-fingered ZFPs targeting the immediate early gene FosB (Heller et al., 2014) or the cyclin-dependent kinase 5 gene (Cdk5) (Heller et al., 2016) in the mouse brain reward region nucleus accumbens was shown to regulate addiction-and depression-related behavioural responses. In these studies, the FosB-ZFPs and CDK5-ZFPs were fused to the histone methyltransferase enzyme G9a to induce targeted di-methylation of histone H3 lysine 9 (H3K9me2), a mark associated with transcriptional repression (Shankar et al., 2013) . Six-fingered ZFPs are the most advanced engineered DNA-binding domains, and several ongoing clinical trials have not demonstrated adverse effects (Gaj et al., 2013; Falahi et al., 2015) . In addition to epi-editors, artificial transcription factors (ATFs) have been used to alter transcription in the brain (Laganiere et al., 2010; Konermann et al., 2013; Heller et al., 2014 Heller et al., , 2016 . For ATFs, fusion of the non-catalytic transactivation domain of the viral protein VP16, or of its tetramer (VP64), to DNA binding domains strongly promotes transcriptional activation, whereas fusion of the super Krü ppel-associated box (KRAB) domain (SKD) induces robust transcriptional silencing. How ATFs regulate gene expression is not fully understood, but their lack of intrinsic catalytic activity suggests that they function transiently, by recruiting other proteins such as histone-modifying enzymes to alter gene transcription (Beltran and Blancafort, 2011; de Groote et al., 2012; Huisman et al., 2013) .
There is an urgent need to elucidate how epigenetic processes regulate the expression of key neuron-related protein coding genes involved in fundamental neurological processes such as neuronal plasticity and memory. A master regulator involved in these processes is the postsynaptic density protein 95 (PSD95), transcribed from the gene discs large homolog 4 (Dlg4). PSD95 is the most abundant scaffolding protein in the excitatory postsynaptic density, interacting and regulating a large number of important molecules for neuronal function such as synaptic glutamate receptors, signalling proteins, adhesion molecules, cytoskeletal proteins, and other scaffolding proteins (van Zundert et al., 2004; Elias and Nicoll, 2007) . We and others have used conventional gain (cDNA) and loss (RNAi) of function approaches to show that PSD95 plays a critical role in organizing the postsynaptic synapse, thereby limiting plasticity and hence stabilizing the neuronal circuitry (ElHusseini et al., 2000; Losi et al., 2003; Charych et al., 2006; Ehrlich et al., 2007; Elias et al., 2008; Henriquez et al., 2013; Bustos et al., 2014) . Moreover, it has been reported that the expression of PSD95 is aberrant in several human disorders that affect the central and peripheral nervous systems, including in Alzheimer's disease, Huntington's disease, schizophrenia, autism spectrum disorders, and pain disorders (Arbuckle et al., 2010; de Bartolomeis et al., 2014; Savioz et al., 2014; Zhang et al., 2014; Hong et al., 2016) .
Targeted Dlg4/PSD95 gene knock-down by RNAi-based approaches could be used in human gene therapies; however, these approaches are not ideal for treating patients suffering chronic brain diseases as the large amounts of RNA required can induce toxicity and moreover their effects are only temporary (Kanasty et al., 2012) . These limitations can be overcome by epigenetic editing of the Dlg4/PSD95 locus. Here we elucidated key epigenetic mechanisms that control Dlg4/PSD95 gene expression during rat hippocampus development. This information, together with the use of genome editing technologies, allowed us to epigenetically reprogram the Dlg4/PSD95 promoter. Such epigenetic editing controlled gene expression both in vitro and in vivo, influencing function and structure of neurons as well as recognition memory in aged mice and in a mouse model of Alzheimer's disease (AbPPswe/PS-1).
Materials and methods
For detailed materials and methods please refer to the Supplementary material.
Animals
All protocols involving rodents were carried out according to NIH and ARRIVE guidelines, and were approved by the Ethical and Bio-security Committees of Universidad Andrés Bello. Wild-type rats (Sprague-Dawley), wild-type mice and AbPPswe/PS-1 mice (004462 from Jackson laboratory) were used.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were used on hippocampal tissue as described (Henriquez et al., 2013) . Briefly, rat hippocampi were double cross-linked, homogenized, and sheared in a water bath sonicator Bioruptor (Diagenode Inc.) to obtain fragments of 500 bp or smaller. Chromatin was immunoprecipitated with specific antibodies recognizing histone post-translational modifications and chromatin-modifying enzymes. Immuno-complexes were recovered with protein A or G agarose beads and DNA was recovered by phenol/chloroform extraction and ethanol precipitation. Quantitative PCR was performed with specific primers for the Dlg4/PSD95 promoter region, Dlg4/PSD95 coding region, or Runx2 P1 promoter region.
Chromatin immunoprecipitation sequencing
Precipitated DNA obtained from ChIP experiments was used to construct libraries, and sequenced using pair-end reads for 300 cycles on a MiSeq TM desktop sequencer (Illumina). Sequences were aligned with Bowtie2 (Langmead and Salzberg, 2012) against the latest Rattus norvegicus genome (rn4) and peak detection was performed using Avadis NGS software (Strand).
Bisulfite sequencing
Sequencing of methylated DNA sequences was performed as described (Falahi et al., 2013; Huisman et al., 2013) . Methylation status of 12 CpGs in the Dlg4/PSD95 DNA promoter sequence was determined by bisulfite sequencing. Genomic DNA was obtained from hippocampal tissue, using the Quick-gDNA TM kit (Zymo Research), following manufacturer's instructions. Genomic DNA was bisulfite-converted with the EZ DNA Methylation-Gold TM (Zymo Research) kit. The region was amplified using specific primers and cloned into pCR2.1 vector (Life technologies) for sequencing.
Engineering of PSD95-6ZF constructs
Dlg4/PSD95 gene promoter sequence was analysed using databases for transcription start sites. The region between À200 and + 100 was screened for putative zinc finger proteins (ZFPs) that comprise 6 zinc fingers fused together (6ZFP) to enable targeting 18 contiguous base pairs (www.zincfingertools.org) (Mandell and Barbas, 2006) . ZFPs with high affinity and target site specificity were selected. The following zinc fingers with high affinity and target site specificity were selected to target the Dlg4/PSD95 promoter DNA sequence: 3 0 -GAATGAGGGGAGGGGAGG-5 0 . The resulting amino acid sequence of the complete PSD95-6ZF is as follows: LEPGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCP-ECGKSFSQAGHLASHQRTHTGEKPYKCPECGKSFSRSDKL-VRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGE-KPYKCPECGKSFSRSDKLVRHQRTHTGEKPYKCPECGKS-FSRSDHLTNHQRTHTGKKTS. The helices that interact with the DNA sequence are underlined. For expression, the construct was subcloned into a pMX-IRES-GFP retroviral vector containing the transcription effector domains VP64, SKD, and the sequence of catalytic domains of the histone methyltransferase enzymes G9a and Suvdel76 (Falahi et al., 2013) . To infect primary hippocampal neurons, all PSD95-6ZF-fusion constructs were subcloned into a lentiviral bicistronic pCDH vector expressing cop-GFP (System Biosciences) and lentiviral particles produced. To infect neurons in vivo, PSD95-6ZF-fusion constructs were subcloned into p1005 herpes simplex virus (HSV) vector, or into adeno-associated virus (AAV) vectors to produce viral particles. All vectors used for HSV, AAV, retroviral and lentiviral production coded for the expression of GFP using an independent promoter.
Viral particles
Lentiviral particles were prepared as described (Henriquez et al., 2013) . To produce retroviral and lentiviral vectors, HEK293FT cells were grown in 100 mm culture plates to 80-90% confluence; Lipofectamine TM 2000 reagent (Life Technologies; following manufacturer's instructions) or CaPO 4 was used to transfect cells with the pMX or pCDH plasmid containing the PSD95-6ZFP and effector domains (VP64, SKD, G9a, or Suvdel76), together with viral packaging plasmids (containing cDNA encoding gag-pol and the vesicular stomatitis virus G protein). Empty pMX or pCDH plasmids (GFP only), and backbones with only PSD95-6ZFPs, were used as control. Also, we made use of HSV viruses (3 Â 10 8 transducing units/ml) expressing GFP alone, or together with PSD95-6ZFP-Suvdel76 or PSD95-6ZFP-VP64. GFP expression in HSVs is driven by a CMV promoter, whereas the gene of interest is driven by an IE4/5 promoter (Neve et al., 2005; van Zundert et al., 2008; Heller et al., 2014) . To allow for an efficient, widespread and long-term transduction of the constructs in the brain, AAV vectors were used. AAV vectors encoding ATFs under a chicken b-actin (CBA) promoter also carried an IRES-GFP cassette. AAV-PHP.B vectors were produced by transient transfection of HEK293 cells followed by purification using iodixanol gradient centrifugation. The AAV-PHP.B capsid gene was synthesized based on the published sequence (Genbank KU056473; Deverman et al., 2016) and cloned in a trans-complementing plasmid carrying the AAV2 Rep gene as previously described (Broekman et al., 2006) .
Stereotaxic injections
Bilateral hippocampal stereotaxic injections of viral particles were performed as previously described for HSV particles Bustos et al., 2017) . Briefly, adult mice were anaesthetized with saline (5 ml saline/gram body weight) containing 170 mg/kg ketamine plus 17 mg/kg xylazine. For spine morphology analysis, 1.0 ml of 10% diluted HSV (0.1 ml of $10 8 infectious units/ml + 0.9 ml HEPES) was injected into dentate gyrus, with the following coordinates: AE 1.5 mm lateral; À2 mm anteroposterior; À2.3 mm ventral from bregma (Tashiro et al., 2006) . For hippocampal electrophysiology recordings, 1.0 ml of 25% diluted HSV (0.25 ml of $10 8 infectious units/ml + 0.75 ml HEPES) was injected into dentate gyrus ( AE1.5 mm lateral; À2 mm anteroposterior; À2.3 mm ventral from bregma), CA1 ( AE 1.5 mm lateral; À2 mm anteroposterior; À1.3 mm ventral from bregma) and CA3 (AE 2.5 mm lateral; À2 mm anteroposterior; À1.5 mm ventral from bregma (Tashiro et al., 2006) . For behavioural studies, HSVs (0.5 ml 25% diluted) or AAVs (0.5 ml undiluted) were bilaterally injected into CA1 and dentate gyrus using the above coordinates.
Spine morphology
Secondary dendrite shafts (530 mm) were selected from granular neurons of the dentate gyrus and high magnification images were acquired with an UltraView RS spinning disk microscope (Perkin Elmer) with a 100Â oil objective (NA = 1.3, CApochromat), excitated with a 488 nm diode laser (Omicron), and captured with a 12-bit CCD camera (Hamamatsu ORCA-ER). Images were deconvolved, segmented and 3D reconstructions made. Total number of spines, spine density along the dendrite, and quantitative morphological descriptors were calculated from the 3D voxel models, as described earlier (Hä rtel et al., 2007) . Spine shapes were defined using the morphological descriptors as follows: (i) filopodia: length 51.5 mm and entropy 50.91; (ii) mushroom: 51.5 mm in length and 40.45 mm in width; (iii) stubby: 51.5 mm in length, 40.45 relative volume and 50.5 mm in elongation; (iv) thin: 51.5 mm length and 50.45 in width or 51.5 mm in length and 40.5 in elongation.
Electrophysiology
Slice preparation and whole-cell electrophysiological recordings on single neurons were performed as previously described (Fuenzalida et al., 2007; Vargas et al., 2014) . All recordings were made with picrotoxin (50 mM, Tocris) in the artificial CSF. The evoked excitatory postsynaptic current (eEPSC) was elicited by bipolar stimulation. The measurement of the NMDA/AMPA receptor ratio was performed similarly as previously described (Myme et al., 2003; Ehrlich et al., 2007) .
Novel object recognition and object location memory tests
The single trail novel object recognition (NOR) and object location memory (OLM) tests consisted of three steps: habituation, a training session (10 min), test session (10 min) 24 h later. Mice were individually habituated in an apparatus that contained a cage inside an insonorized chamber. In the training session, the cage contained two identical objects, termed 'familiar objects' in NOR and 'non-displaced objects' in OLM. In the NOR test session, one familiar object (F) was replaced by a novel object (N). In the OLM test session, the location of one non-displaced object (non-D) was changed, termed displaced object (D). The exploration time was recorded and defined as time spent sniffing or touching the object with the nose and/or forepaws. For NOR, the 'recognition index' was calculated by the time spent to explore object N compared to total time explored in both objects (N + F). For OLM, the 'discrimination index' was calculated by the time spent to explore object D compared to total time explored in both objects (D + non-D).
Memory flexibility test
The memory flexibility task was performed as previously described (Serrano et al., 2014) with slight modifications. The mice were trained in a circular water maze to find a circular platform of 10 cm localized at 1 cm below water level. Each animal was trained for one pseudo-random location of the platform per day for 4 days, with a new platform location each day. The maximum swimming trial duration was 60 s and animals were allowed to spend 10 s on the platform at the end of each trial. Up to 15 training trials were performed per day or until the animal met a criterion of three successive trials within an escape latency of 520 s.
Statistical analyses
One-way ANOVA followed by the Dunnett's post hoc was used to detect intervals, in which significant changes occurred, for all datasets where a parameter was measured PSD95-6ZFs regulate plasticity and memory BRAIN 2017: 140; 3252-3268 | 3255 across time points following a specific treatment. Student's t-test was applied when two populations of responses were examined. For all figures, error bars represent the standard error of the mean (SEM); *P 4 0.05, **P 4 0.01, ***P 4 0.001.
See Supplementary material for more details on the methods described above and on cell cultures, transfections and infections;
qRT-PCR assays; western blot assays; synaptic membrane preparations; dendritic arbor analysis in vitro.
Results
Histone modification patterns at the Dlg4/PSD95 gene promoter in developing hippocampus
To gain understanding in the epigenetic mechanisms that control Dlg4/PSD95 gene expression in the maturing hippocampus, we first assessed Dlg4/PSD95 mRNA and protein levels. We observed a gradual increase in Dlg4/ PSD95 mRNA and protein levels throughout the developing rat hippocampus [embryonic Day 18 (E18), and postnatal Days 10 (P10), 30 (P30) and 590 (P90)], with highest levels found in adult hippocampus ( Fig. 1A and B). Next, we investigated if this Dlg4/PSD95 expression pattern was related with an increase in active or a decrease in silencing epigenetic marks at the Dlg4/PSD95 promoter by using antibodies against specific histone H3 modifications to perform ChIP, followed by quantitative PCR (ChIP-qPCR) with primers for the Dlg4/PSD95 promoter (see model, Fig. 4A ). We found that the increased expression was associated with gradual enrichment of the active marks H3K9ac (Fig. 1C) , H3K27ac (Fig. 1D ), H3K4me3 ( Fig. 1E ), but not H3K14ac ( Fig. 1F ; and see below) at the proximal Dlg4/PSD95 gene promoter. Levels of H3 ( Fig.  1G ) and H4 (not shown) gradually decreased throughout development, indicating that enhanced Dlg4/PSD95 gene expression was accompanied by progressive nucleosome Figure 1 Concomitant with the upregulation of Dlg4/PSD95 gene expression during development, its promoter becomes enriched for active histone tail marks. (A) Total RNA was extracted from hippocampal tissues on E18, P10, P30 or 5P90, and Dlg4/PSD95 mRNA levels were quantified by qRT-PCR. Results were normalized against mRNA levels of GAPDH. E = embryonic day; P = postnatal day. (B) Levels of PSD95 protein were analysed by western blots of whole cell extracts from hippocampal tissues, using antibodies against PSD95 (N-cadherin served as loading control). (C-G) ChIP assays were performed on chromatin from hippocampal tissue at indicated developmental stages, using antibodies against (C-F) active histone tail modifications, or (G) histones in the following order: (C) H3K9ac, (D) H3K27ac, (E) H3K14ac, (F) H3K4me3, or (G) histone H3. Specific primers for the Dlg4/PSD95 gene promoter, encompassing the transcription start site (TSS), were used to quantify precipitated DNA by qPCR (see Fig. 4A ). All results were normalized against input material; non-specific IgG served as control. Bars represent mean AE SEM from at least three independent experiments. Statistical analysis was performed using ANOVA test. *P 5 0.05, **P 5 0.01 and ***P 5 0.001, relative to E18.
depletion. Based on these findings we also analysed the data after normalizing for the amount of histones associated with Dlg4/PSD95 promoter region and observing that H3K9ac (Fig. 1C) , H3K27ac (not shown) and H3K4me3 (not shown) were significantly higher enriched throughout hippocampal development, while the H3K14ac mark remained unchanged from E18-P30, and significantly increased 4P90 (inset Fig. 1F ). To complement the results of acetylated active marks, we examined the enrichment of three histone acetyltransferases, CREB-binding protein (CBP) ( Fig. 2A) , p300 (Fig. 2B) , and GCN5 (Fig. 2C) . All of them were gradually enriched at the Dlg4/PSD95 gene promoter with hippocampal maturation. The developmental enrichment of the active mark H3K4me3 at the Dlg4/ PSD95 promoter (Fig. 1F ) was accompanied by increased association of the critical component of its writer complex Wdr5 (Fig. 2D) .
Next, we analysed the presence of transcriptional silencing marks. H3K9me2 and H3K9me3 were not detected at the Dlg4/PSD95 gene promoter throughout hippocampal development ( Fig. 3A and B ; grey bars). In contrast, these marks were observed for the Dlg4/PSD95 gene promoter in the myoblastic cell-line C2C12 ( Fig. 3A and B ; black bars), where this gene is not actively transcribed (Fig. 3F) . We also found that G9a (Fig. 3C) and Suv39H1 (Fig. 3D) -two histone methyltransferase enzymes that di-and tri-methylate H3K9, respectively (Shankar et al., 2013) -were highly associated with the Dlg4/PSD95 gene promoter in the myoblastic cell-line C2C12 ( Fig. 3C and D ; black bars), while their binding was not detected at this site in hippocampal tissue ( Fig. 3C and D ; grey bars). DNA methylation of CpG nucleotides in promoter regions is another important epigenetic mechanism used to silence gene transcription (Cedar and Bergman, 2012) . Bisulfite sequencing analysis revealed that of the 12 CpGs present in the Dlg4/PSD95 proximal gene promoter region within the first $400 bp upstream of transcription start sites (Zhang et al., 2003) , none were methylated in the hippocampus at any developmental stage tested ( Fig. 3E ; white circles), while two CpG sites were methylated in the myoblastic cell line C2C12 ( Fig. 3E ; black circles).
Altogether our results show that increased expression of Dlg4/PSD95 in the maturing rat hippocampus is accompanied by the gradual enrichment of active histone marks. Unexpectedly, neither typical repressive histone H3K9me2/ 3 marks nor DNA methylation were detected at the proximal Dlg4/PSD95 gene promoter in hippocampal cells, not even at early developmental stages when Dlg4/PSD95 expression is very low. ChIP assays were performed on chromatin prepared from hippocampal tissue at the indicated developmental stages, using antibodies against the chromatin-modifying enzymes (A) CBP, (B) p300, (C) GCN5, or (D) Wdr5. Dlg4/ PSD95 primers were used for qPCR. Results were normalized against input material and non-specific IgG served as control. Bars represent means AE SEM from at least three independent experiments. Statistical analysis was performed using ANOVA test. *P 5 0.05, **P 5 0.01 and ***P 5 0.001, relative to E18.
Design of a 6ZF construct that specifically targets the Dlg4/PSD95 gene promoter Next, we explored an epigenetic editing strategy to control specifically the Dlg4/PSD95 transcriptional status in hippocampal neurons. We sought to induce the recruitment of chromatin-modifying enzymes to the Dlg4/PSD95 gene promoter capable of overwriting the original chromatin signature. Particularly, we engineered a DNA module containing six Cys2His2 zinc fingers (6ZF) to target an 18-bp sequence located in the proximal Dlg4/PSD95 promoter region (À38 to À21), upstream of the transcription start sites (Fig. 4A) ; the length of this sequence should theoretically provide unique sequence specificity (Gaj et al., 2013; Falahi et al., 2015) . We incorporated also a haemagglutinin (HA)-tag and a nuclear localization signal into the PSD95-6ZF. Then, to determine whether the engineered DNA-binding zinc-finger motif effectively targeted the Dlg4/PSD95 gene promoter sequence, cultured rat hippocampal neurons were . The PSD95-6ZF construct is fused to diverse effector domains to generate PSD95-6ZF-VP64, PSD95-6ZF-SKD, PSD95-6ZF-G9a or PSD95-6ZF-Suvdel76. The colour coding designed to the diverse constructs refers to gene transcription: black (neutral), green (activation) and red (repression). Red arrows indicate primers used to quantify the ChIP assays by qPCR. (B) Hippocampal neurons (in vitro Day 7) were infected with lentiviral vectors coding for GFP (Control) or PSD95-6ZF-NoED; at in vitro Day 12, ChIP assays were performed using an HA antibody (grey bar). Results were normalized against input material, and non-specific IgG served as a control (white bar). See also Supplementary Figs 1 and 2 for ChIP-seq. (C-I) N2a cells were infected for 72 h with the diverse constructs, as depicted. Total Dlg4/PSD95 mRNA and protein levels were measured by (C) qRT-PCR or by (D) western blot (top, N2a cells; bottom, hippocampal neurons), respectively. (E-H) ChIP-qPCR analyses using antibodies against (E) H3K9me2, (F) H3K9me3, (G) total histone H3, or (H) total histone H3 acetylation. Bars represent means AE SEM from three independent experiments, and statistical analysis was performed by (B) Student's t-test or (C-H) one-way ANOVA. ***P 5 0.001, relative to control. (I) Bisulfite sequencing analysis performed on 12 CpG sites located in Dlg4/ PSD95 promoter (as in Fig. 3E ). See also Supplementary Fig. 3 for additional specificity of the 6ZF-fusion constructs.
transduced with a lentivirus vector encoding PSD95-6ZF-NoED (NoED, no effector domain). ChIP-qPCR assays revealed that PSD95-6ZF-NoED was strongly enriched at the Dlg4/PSD95 gene promoter (Fig. 4B) . To confirm the specificity of PSD95-6ZF-NoED, we used whole-genome ChIP sequencing (ChIP-seq) technology. Genome-wide karyotype visualization of the ChIP-seq data showed that PSD95-6ZF-NoED was specifically and efficiently recruited to the chromosome 10q24 locus-where the Dlg4/PSD95 gene resides in rats (Supplementary Fig. 1 )-with highest peaks (74 reads) mapped to the proximal promoter region of the Dlg4/PSD95 gene (chr10:56 861 701-56 863 601) ( Supplementary Fig. 2A ). As an internal control, we analysed samples exposed to an unrelated non-specific IgG (blue) and to input (green). Other sequences also showed some off-target binding of PSD95-6ZF-NoED, which were not associated with known promoter regions. The most significant of these was the rat Frizzled 1 (Fzd1) locus (chr4:25 995 704-25 995 985) ( Supplementary Fig. 1 ), with weak binding (17 reads) of PSD95-6ZF-NoED at its coding sequence; however, this binding was also found in the IgG sample ( Supplementary Fig. 2B ).
PSD95-6ZF-fusion constructs induce epigenetic reprogramming and bidirectionally control Dlg4/PSD95 gene expression in N2a cells
The 6ZF DNA binding module was fused to various effector domains to induce either activation or repression of the Dlg4/PSD95 gene through direct transcriptional or epigenetic mechanisms. To promote robust transcriptional activation of the Dlg4/PSD95 gene, we first linked the DNA-binding module of the PSD95-6ZF to the transactivator domain of VP64 (tetramer of viral protein VP16) to generate the ATF PSD95-6ZF-VP64 (Fig. 4A) . Conversely, to induce strong transcriptional repression, the PSD95-6ZF module was fused to the SKD to generate ATF PSD95-6ZF-SKD (Fig. 4A) . To achieve sustained gene expression modulation, epigenetic editing can be induced by fusing catalytic domains of histone modifying enzymes to a zinc-finger DNA-binding module, generating synthetic ZFPs. Considering that in myoblastic cell-line C2C12 Dlg4/ PSD95 gene silencing was strongly associated with enrichment of the repressive marks H3K9me2 and H3K9me3 (Fig. 3A and B, black bars) , and their histone methyltransferases G9a and SUV39-H1 (Fig. 3C and D, black bars) , respectively, we engineered PSD95-6ZF-G9a and PSD95-6ZF-Suvdel76 to induce specific targeted rewriting of histone tails associated with silenced Dlg4/PSD95 gene promoters to achieve Dlg4/PSD95 gene repression (Fig. 4A) .
To investigate whether the PSD95-ZFPs and PSD95-ATFs alter Dlg4/PSD95 gene expression through defined epigenetic editing, N2a neuroblastoma cells were infected with retroviruses containing the diverse PSD95-6ZF-fusion constructs and 72 h later Dlg4/PSD95 mRNA and PSD95 protein levels were quantified (Fig. 4C and D) and ChIP assays performed (Fig. 4E-H) . PSD95-6ZF-G9a and PSD95-6ZF-Suvdel76 produced robust Dlg4/PSD95 gene repression ( Fig. 4C and D) , which was accompanied by strong de novo di-and tri-methylation of H3K9, respectively, at the Dlg4/PSD95 gene promoter ( Fig. 4E and F) .
Expression of PSD95-6ZF-SKD also led to Dlg4/PSD95 gene repression and a moderate presence of the H3K9me2 and H3K9me3 marks (Fig. 4E and F) , indicating that SKDdependent repression is, in part, mediated by (or resulting in) recruiting histone methyltransferases to the Dlg4/PSD95 gene promoter. H3K9me2/3 marks were not observed following infection with GFP (control) or PSD95-6ZF-NoED. ChIP assays furthermore showed that histone H3 proteins levels associated to the Dlg4/PSD95 gene promoter were not altered by any of the conditions (Fig. 4G) , while expression of PSD95-6ZF fused to SKD, G9a, or Suvdel76 diminished H3 acetylation (Fig. 4H) .
Conversely, we demonstrated that expression of PSD95-6ZF-VP64 strongly enhanced levels of Dlg4/PSD95 mRNA (Fig. 4C) . At the protein level, PSD95-6ZF-VP64 increased PSD95 expression only slightly in N2a cells (Fig. 4D , upper blots) but more robustly in hippocampal neurons (Fig. 4D , lower blots). Further analyses of N2a cells revealed that enhanced Dlg4/PSD95 gene expression was accompanied by a strong increase in the presence of the H3ac mark (Fig. 4H) , suggesting that PSD95-6ZF-VP64 contributes to transcriptional activation of the Dlg4/PSD95 gene through (direct or indirect) recruitment of histone acetyltransferases.
Using bisulfite sequencing analysis, we found that none of the 12 CpGs sites located in the Dlg4/PSD95 proximal gene promoter sequence were methylated following transduction with any of the PSD95-6ZF-fusion constructs (Fig.  4I) . Collectively, our results indicate that PSD95-6ZF-G9a, PSD95-6ZF-Suvdel76, and PSD95-6ZF-SKD repress Dlg4/ PSD95 gene expression by epigenetic reprogramming of histone H3 associated with the Dlg4/PSD95 gene promoter, without methylating the promoter DNA sequence. Conversely, the designed ATF PSD95-6ZF-VP64 activates Dlg4/PSD95 gene expression by increasing activating histone post-translational modification.
Phenotypic rescue experiments were conducted in hippocampal cultures to demonstrate the specificity of the PSD95-6ZF-fusion constructs and to rule out off-target effects. Given that large scale dendritic structural alterations of cultured hippocampal neurons are highly influenced by Dlg4/PSD95 gene expression (Charych et al., 2006; Henriquez et al., 2013; Bustos et al., 2014) , the effects of the PSD95-6ZF-fusion constructs on hippocampal dendritogenesis in the absence and presence of conventional gain (cDNA) and loss (RNAi) of function approaches were determined. We found that expression of short-hairpin RNA that knocked-down Dlg4/PSD95 counteracted PSD95-6ZF-VP64-mediated reduction of dendritogenesis ( Supplementary Fig. 3A and B) . Conversely, overexpression of Dlg4/PSD95 cDNA neutralized the effects of PSD95-6ZF-SKD ( Supplementary Fig. 3C and D) .
PSD95-6ZF-fusion constructs are effective modulators of Dlg4/PSD95 gene expression in vivo and affect plasticity-associated processes Previous gain-and loss-of-function studies revealed a critical role for PSD95 in dendritic spine maturation, as visualized by the ratio of mature mushroom spines versus filopodia-like structures (El-Husseini et al., 2000; Ehrlich et al., 2007; Bustos et al., 2014) . We wanted to determine if modulation of Dlg4/PSD95 expression levels with our novel PSD95-6ZF-fusion constructs was an effective approach to control spine morphology in vivo. To achieve this, we used recombinant HSV vectors with the PSD95-6ZF-fusion cDNAs placed under the IE4/5 promoter and enhanced green fluorescent protein (eGFP) expression driven by a CMV promoter to visualize transduced cells (Fig. 5A) . HSV vectors expressing only eGFP under the CMV promoter were used as control (HSV-Ctrl). HSVmediated transgene expression is fast (within hours) and robust, facilitating detailed morphological analyses. Because HSV-mediated transgene expression peaks at Day 3 and then largely dissipates by Day 6 (Barrot et al., 2002;  data not shown), all the experiments with this virus were performed at 3-4 days post-infection (dpi).
We found that infection of hippocampal cells in vivo with HSV-PSD95-6ZF-Suvdel76 or HSV-PSD95-6ZF-VP64 led to decreased or increased Dlg4/PSD95 mRNA expression, respectively, relative to HSV-Ctrl (Fig. 5B) . Next, we examined if expression of the specific PSD95-6ZF-fusion constructs regulates spine maturation. To accomplish this, we infected the dentate gyrus of the hippocampus in 8-month-old mice with the specific HSVs and analysed spine morphology and density 3 dpi (Fig. 5C-G) . Dendritic protrusions on second order branches of selected granular cells were classified based on their size and shape. As shown earlier (Jain et al., 2012; Ampuero et al., 2017) , granular cells in mature mice display substantial numbers of thin, stubby and mushroom spines, and had few filopodia (Fig. 5D-G) . Overall spine density was maintained in neurons expressing PSD95-6ZF-Suvdel76 or PSD95-6ZF-VP64 (Fig. 5E ). Consistent with findings that PSD95 participates in spine maturation in vitro (El-Husseini et al., 2000; Ehrlich et al., 2007; Bustos et al., 2014) , dentate gyrus neurons expressing PSD95-6ZF-VP64 led to a higher density of mushroom spines (Fig. 5F ), that displayed an increased volume (Fig.  5G) . Expression of PSD95-6ZF-Suvdel76 in vivo for 3 days did not affect these parameters (Fig. 5F and G) . (Losi et al., 2003; van Zundert et al., 2004; Elias et al., 2008; Bustos et al., 2014) . To determine whether our PSD95-6ZF-fusion constructs alter excitatory synaptic transmission, dentate gyrus neurons in adult mice were infected with the specific HSVs, and 3-4 dpi acute slices were prepared to perform electrophysiological recordings from GFPpositive neurons. Our data indicate that HSV-PSD95-6ZF-Suvdel76 yielded a significant decrease in the NMDA/ AMPA ratio relative to control, that seemed to be the result of a strong decrease in NMDA-mediated eEPSCs and, to a lesser extent, in AMPA-mediated eEPSCs (Fig. 5H and I) . The NMDA/AMPA ratio in neurons infected with HSV-PSD95-6ZF-VP64 was similar to controls, and appeared to be the result of increases in both eEPSC NMDA receptors and eEPSC AMPA receptors ( Fig. 5H and I) . Paired pulse ratios were not significantly different between HSV-Ctrl (91 AE 8%; n = 6), HSV-PSD95-6ZF-Suvdel76 (97 AE 8%; n = 5), and HSV-PSD95-6ZF-VP64 (110 AE 8%; n = 5), indicating that presynaptic release of glutamate was similar in the different conditions. Together, our studies in mice demonstrate that modulation of Dlg4/PSD95 gene expression by engineered PSD95-6ZF-fusion constructs targeting the Dlg4/ PSD95 locus is sufficient to regulate synapse and spine maturation of hippocampal neurons in vivo.
PSD95-6ZF-VP64 improves learning and memory deficits in aged and AbPPswe/PS-1 mice
We also examined if PSD95-6ZF-VP64 transduction could recover learning and memory deficits in aged mice and in a mouse model of Alzheime's disease (AbPPswe/PS-1); both models display memory impairments accompanied by a loss of PSD95 expression (de Bartolomeis et al., 2014; Savioz et al., 2014; Hong et al., 2016) . We used a novel object recognition (NOR) test, a simple single trial behavioural memory task that relies primarily on a rodent's innate preference for novel versus familiar objects when allowed to explore freely; specifically, hippocampal-mediated memory impairments are evidenced when animals do not discriminate between a novel and familiar object 24 h after training. As expected, aged wild-type mice (15-18-month-old) performed poorly in the NOR test, showing limited exploration of the novel objects relative to younger (5-month-old) wild-type mice ( Supplementary Fig. 4) . Next, aged animals were equally divided in two groups and bilaterally injected in the hippocampus (CA1 and dentate gyrus) with either HSV-Ctrl or HSV-PSD95-6ZF-VP64, and animals were tested for NOR 3 dpi. Interestingly, our results revealed that treatment with HSV-PSD95-6ZF-VP64, but not HSV-Ctrl, reverted the NOR impairment in aged mice, reaching levels comparable to those found in young mice ( Supplementary Fig. 4) .
Next, we evaluated if PSD95-6ZF-VP64 transduction could prevent or recover hippocampal dysfunction associated with learning and memory deficits in AbPPswe/PS-1 Figure 5 Viral-mediated expression of PSD95-6ZF-fusions in the hippocampus in vivo regulate spine morphology and AMPA receptor-mediated synaptic activity. HSV vectors expressing eGFP alone (HSV-Ctrl), eGFP plus PSD95-6ZF-Suvdel76 (HSV-PSD95-6ZF-Suvdel76), or eGFP plus PSD95-6ZF-VP64 (HSV-PSD95-6ZF-VP64) were generated. (A) Mice were injected bilaterally with HSVs into the CA1, CA3 and dentate gyrus (DG) (indicated by the asterisk). Three days post-injection (dpi), hippocampi were isolated, fixed, and sliced to show infection efficiency by confocal microscopy. (B) To measure Dlg4/PSD95 mRNA levels by qRT-PCR, dorsal hippocampi were isolated 6 hr postinjection. (C-I) For spine morphology and electrophysiology, 8-week-old mice were only injected into dentate gyrus; 3 dpi, slices were prepared on (C-G) fixed or (H and I) unfixed brain. (C) Fluorescent images at 10Â or 60Â (inset) show infected dentate gyrus neurons; only secondary dendritic processes were analysed. (D) 3D active surface models of dendrite morphology. Dendritic protrusions or spines were classified as filopodia (F), thin (T), stubby (S), or mushroom (M). (E-G) Graphs show quantification of (E) spine density, (F) spine morphology, or (G) mushroom volume of dentate gyrus neurons expressing the diverse PSD95-6ZF constructs. (H) Using whole-cell patch-clamp recordings, eEPSCs of GFP-positive dentate gyrus neurons were analysed. Representative traces of neurons infected with HSV-Ctrl, HSV-PSD95-6ZF-Suvdel76, or HSV-PSD95-6ZF-VP64 are shown. (I) Quantification of average NMDA/AMPA ratios as indicated. Bars represent means AE SEM from five to six neurons per condition; statistical analysis was performed using Student's t-test. *P 5 0.05, **P 5 0.01, ***P 5 0.001, relative to control.
mice. As expected, all non-infected AbPPswe/PS-1 mice (6 months old) performed poorly in the NOR test, compared to age-matched wild-type mice (Fig. 6A-D) . Next, AbPPswe/ PS-1 mice were equally divided in two groups and injected bilaterally in the hippocampus with either recombinant AAV vectors encoding PSD95-6ZF-VP64 plus GFP (AAV-PSD95-6ZF-VP64) or only GFP as control (AAV-Ctrl) (scheme in Fig. 6A ). Given that AAVs allow long-term transgene expression in vivo with limited (or undetected) toxicity, AAVs are the preferential vehicles for gene therapy, including for patients suffering brain diseases (Mingozzi and High, 2013) . To achieve stable and widespread transgene expression in the hippocampus, AAV vectors with the novel PHP.B capsid were generated (Deverman et al., 2016) . We found that AbPPswe/PS-1 mice (6-8 months old) infected for 2.5 weeks with AAV-PSD95-6ZF-VP64 expressed significant increased PSD95 protein levels relative to animals injected with AAV-Ctrl [1.26 AE 0.08 (n = 4 per condition); *P 5 0.05 Student's t-test; Fig. 6B ]. Importantly, treatment of AbPPswe/PS-1 mice (6.5 months old) for 2.5 weeks with AAV-PSD95-6ZF-VP64, but not AAV-Ctrl, rescued the NOR impairment, reaching levels comparable to wild-type mice ( Fig. 6C and D) . Additionally, these AAV-PSD95-6ZF-VP64-treated AbPPswe/PS-1 mice improved in the object location memory (OLM) test, a simple single trial spatial memory task (Supplementary Fig. 5 ). Subsequently, we tested the same AbPPswe/PS-1 mice for spatial learning performance using an adapted Morris water maze task. The Morris water maze task relies on distal cues that guide rodents from start locations around the perimeter of an open circular water maze to locate a submerged escape platform. Memory flexibility, in which the platform is changed each day, has been proven more sensitive than the classical Morris water maze task to evaluate hippocampal-dependent spatial-based learning and memory across several days (Chen et al., 2000; Serrano et al., 2014) . Memory flexibility was not affected in AbPPswe/PS-1 mice until they reached 12 months of age (data not shown). Interestingly, and as indicated by the fewer trials to achieve the learning criterion, we found that AAV-PSD95-6ZF-VP64-treated AbPPswe/PS-1 mice showed significantly improved memory flexibility scores relative to untreated and AAV-GFP-treated AbPPswe/PS-1 animals, reaching levels that are comparable to those found in young 5-month-old wild-type mice (Fig. 6E) .
After testing memory flexibility, mice were sacrificed to determine infection efficiency and PSD95 expression levels. Confocal images show robust GFP expression in the soma and projections of hippocampal pyramidal neurons of AbPPswe/PS-1 mice infected with AAV-PSD95-6ZF-VP64 or AAV-Ctrl (Fig. 6F) . Finally, we determined whether AAV-PSD95-6ZF-VP64 increased PSD95 protein expression at hippocampal synapses in AbPPswe/PS-1 mice. To achieve this, synaptic membranes of pooled hippocampi (three mice/condition) were prepared. We found increased synaptic PSD95 protein levels in AbPPswe/PS-1 mice (12 months old) infected 5 months earlier with AAV-PSD95-6ZF-VP64 relative to animals injected with AAV-Ctrl (Fig.   6G, upper blots) . Homogenates of these same pooled samples revealed that total PSD95 protein levels were also increased in AbPPswe/PS-1 mice treated with AAV-PSD95-6ZF-VP64 (Fig. 6G, lower blots) . To determine total PSD95 protein levels of individual hippocampi, in independent experiments AbPPswe/PS-1 mice (7 months old) were treated for 5 months with AAV-PSD95-6ZF-VP64 or AAV-PSD95-6ZF-NoED, as control. Expression of PSD95-6ZF constructs containing VP64, but no effector domain (NoED), increased PSD95 protein levels in individual hippocampi derived from 12-month-old AbPPswe/PS-1 mice, reaching levels comparable to those found in age-matched wild-type mice (Supplementary Fig. 6 ). Together, we found that transduction of the ATF PSD95-VP64 increased PSD95 expression and rescued memory deficits in aged and Alzheimer's disease mice.
Discussion
Here we elucidated epigenetic mechanisms that control Dlg4/ PSD95 gene expression during rat hippocampus development. The established epigenome landscape, together with the generation of PSD95-6ZF-fusion constructs, allowed us to alter the expression of Dlg4/PSD95 through epigenetic mechanisms. The PSD95-6ZF-fusion constructs regulated various neural plasticity-associated processes and validated PSD95 as a key player in plasticity and memory. Importantly, this work also establishes epigenome editing as a potential therapy to treat human neurological disorders with PSD95-dependent cognitive impairments. Use of zinc finger constructs to alter gene expression has advantages over more conventional loss-and gain-of-function approaches. First, engineered transcription factors can regulate expression of mRNAs that include all potential splice variants in a physiological context. This could be important for PSD95 as it has been demonstrated that expression of PSD95 isoforms is required to mediate synaptic strengthening by activity-dependent and activity-independent mechanisms (Schlü ter et al., 2006) . Second, engineered transcription factors have been shown to induce long-lasting changes in gene expression when fused to effector domains that alter histone tail modifications or the methylation status of genomic DNA sequences (de Groote et al., 2012; Stolzenburg et al., 2015) . Importantly, although studies in cell lines indicate that the maintenance of induced epigenetic modifications is dependent on the genomic context of the cells (Kungulovski et al., 2015; Cano-Rodriguez et al., 2016) , stability of epigenetic alterations by epigenome editing tools has not been assessed in post-mitotic cells such as neurons.
Repressive histone post-translational modifications and DNA methylation contribute to prevent the expression of certain genes and enable cells to define a specific identity (Bannister and Kouzarides, 2011; Gardner et al., 2011) . Surprisingly, however, the proximal Dlg4/PSD95 gene promoter in hippocampal cells lacks the classic repressive histone marks H3K27me3 (Henriquez et al., 2013) and (A) Scheme of experiment. AAV-PHP.B carrying GFP alone (AAV-Ctrl) or GFP plus PSD95-6ZF-VP64 (AAV-PSD95-6ZF-VP64) were generated and injected in 6.5-month-old AbPPswe/PS-1 mice into the hippocampus (CA1 and dentate gyrus, as indicated by red dots). NOR task was performed before (age 6 months) and after (age 7 months) AAV injections. After testing memory flexibility (MF) (age 12 months), mice were sacrificed to test infection efficiency by immunofluorescence (IF) and PSD95 expression levels by western blot (WB), respectively. (B) Total PSD95 protein levels were analysed by western blot using total protein extracts from individual hippocampi derived from AbPPswe/PS-1 mice Consortium et al., 2015) . Why such discrepancies occur is unclear, but they highlight the need for validating histone post-translational modification patterns in specific loci of the biological material of interest before performing epigenomic editing to test causal links to given traits or diseases.
In addition to repressive marks, here we show that typical activating marks (i.e. H3K9ac, H3K27ac, H3K4me3) are minimally present at the Dlg4/PSD95 gene promoter in embryonic hippocampal cells, similarly as shown in embryonic stem cells (ENCODE Project Consortium, 2012; Roadmap Epigenomics Consortium et al., 2015) . As the hippocampus develops, however, these activating marks are increasingly deposited at the Dlg4/PSD95 gene promoter. Concurrently, we found an increased enrichment of CBP/p300, GCN5, and Wdr5 at the Dlg4/PSD95 gene promoter, chromatin-modifying enzymes and complexes implicated in depositing H3K9ac, H3K27ac and H3K4me3, respectively (Bannister and Kouzarides, 2011) . These enzymes are also implicated in recruiting RNA polymerase cofactors (Bannister and Kouzarides, 2011) , and in agreement, we previously found that active RNA polymerase II is enriched at the Dlg4/PSD95 gene promote during hippocampal development (Henriquez et al., 2013) . We also detected that phosphorylated CREB is increasingly enrichment at the Dlg4/PSD95 gene promoter during hippocampal development (not shown). Calcium influx through stimulated synaptic NMDA receptors, or voltage-sensitive calcium channels, results in phosphorylation and hence activation of CREB to initiate a transcriptional program of plasticity-associated genes (including Dlg4/PSD95) that drives spine maturation (West et al., 2001; West and Greenberg, 2011) . Given that phosphorylated CREB (Hardingham et al., 1999) and GCN5 (Agalioti et al., 2000) recruit CBP to promoters, alone or with the highly homologous co-activator p300, the presented work also provides important insights in how signalling pathways regulate epigenetic processes to control Dlg4/PSD95 gene expression during rat hippocampus development.
To demonstrate a causal relationship between epigenetic modifications at the plasticity Dlg4/PSD95 gene promoter and its expression, we engineered PSD95-6ZF-fusion constructs. The proximal Dlg4/PSD95 promoter region (À38 to À21) was selected because it is: (i) close to the transcription start sites of the Dlg4/PSD95 gene promoter, a region that typically is poorly enriched in nucleosomes (Jiang and Pugh, 2009) , enabling greater access to transcription factors, including ZFPs; and (ii) highly conserved Figure 6 Continued treated for 2.5 weeks with AAV-Ctrl or AAV-PSD95-6ZF-VP64 at 6-8 months old. Actin was used as loading control. (C and D) Single-trail NOR was performed on AbPPswe/PS-1 mice and wild-type mice and shown as (C) normalized exploration time and (D) recognition index. The recognition index corresponds to the time spent to explore the novel object, divided by the total time spent exploring both objects; an index of 0.5 indicates that mice do not discriminate between a novel and familiar object. Values represent mean AE SEM from 56 mice per condition. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test. **P 5 0.01, ***P 5 0.001. See also Supplementary  Fig. 5 for additional OLM test performed after NOR. (E) The continuous multiple-trial memory flexibility task was performed for 4 days on 12-month-old AbPPswe/PS-1 mice and 5-month-old young wild-type mice 24 h after training. Values represent mean AE SEM from 54-6 mice per condition for both (left) line and (right) bar graph. Two-way ANOVA followed by Bonferroni post hoc test for the line graph (left) revealed significant differences in the learning curve (Days 1-4): # P 5 0.05 AAV-PSD95-6ZF-VP64-treated AbPPswe/PS-1 mice relative to AAV-GFP-treated AbPPswe/PS-1 mice (hash symbol shown in red in left panel); ### P 5 0.001 (not shown) untreated AbPPswe/PS-1 mice relative to AAV-PSD95-6ZF-VP64-treated AbPPswe/PS-1 mice and young wild-type. For simplicity, bar plot (right) shows the average mean of trail to criterion for Days 1 to 4. One-way ANOVA followed by Bonferroni post hoc test revealed significant differences as indicated: *P 5 0.05 and **P 5 0.01. (F) Representative confocal image of CA1 and CA3 12-month-old AbPPswe/PS-1 mice infected with (top row) AAV-Ctrl or (bottom row) AAV-PSD95-6ZF-VP64 at age 6.5 months. High GFP levels are observed in pyramidal neurons with their soma located in the stratum pyramidale (SP) and their dendrites projecting into the stratum radiatum (SR). (G) Western blot of synaptic membranes (top blots) and homogenates (bottom blots) of pooled hippocampi from three mice per condition: Control 12-15-month-old wild-type mice (WT), 12-month-old AbPPswe/PS-1 mice treated with AAV-Ctrl or AAV-PSD95-6ZF-VP64 at age 6.5 months. Expression of PSD95 and actin (loading control) are shown.
across diverse vertebrate species, sharing 100% identity across mouse, rat and human. We found that PSD95-6ZF fused to G9a, Suvdel76, or SKD repressed Dlg4/PSD95 expression concomitant with de novo di-and tri-methylation of H3K9 at the Dlg4/PSD95 gene promoter. In non-neuronal cells, it has been documented that the H3K9me2/3 mark maintains and spreads heterochromatin by creating a docking site for chromodomain-containing proteins, like heterochromatin protein 1 (HP1), which in turn recruits DNA methyltransferases and/or nucleosome remodellers (Smith and Meissner, 2013) . However, de novo H3K9 methylation at the Dlg4/PSD95 gene promoter in N2a cells is neither associated with CpG methylation nor with increased enrichment of histone H3, arguing against heterochromatin formation at the Dlg4/PSD95 gene locus by the engineered ZFPs in our experimental set-up. We also found that H3K9 methylation is correlated with a reduced acetylation of histone H3 in N2a cells that express PSD95-6ZF fused to G9a, Suvdel76, or SKD. Similar G9a-containing ZFPs induce hypo-acetylation in some cell types (cancer cell lines; Falahi et al., 2013) , but not in others (neurons; Heller et al., 2014) . Whether the H3K9me2/3 mark recruits epigenetic enzymes that alter the DNA methylation, and/or the histone acetylation status, thus likely depends on the gene-and/or chromatin context of the target cell. We also found that the designed ATF PSD95-6ZF-VP64 activates Dlg4/PSD95 gene expression, at least in part through epigenetic mechanisms involving increased H3 acetylation. We further demonstrated that the engineered PSD95-6ZF-fusion constructs altered PSD95 levels, synapse and spine maturation in hippocampal neurons in vivo. More importantly, we also show that the PSD95-ATF rescues recognition memory deficits in aged mice and a mouse model of Alzheimer's disease. This is the first study that establishes gene targeting as a potential therapy to ameliorate memory impairments in human neurological disorders.
In conclusion, our study has broad biological implications as the hippocampal epigenome analysis and targeted epigenetic editing with the novel designed PSD95-6ZF-fusion constructs provide important insights into the epigenetic mechanisms underlying neuronal plasticity and learning and memory. Our work also has broad therapeutic implications as the novel designed engineered transcription factors specifically and efficiently bind to the rat Dlg4/ PSD95 locus in hippocampal neurons at a target sequence that is highly conserved across vertebrate species (100% identity among mice, rats, and humans). Thus, our novel engineered PSD95-6ZF-fusion constructs are attractive candidates for future gene therapies in several human central and peripheral nervous system disorders where Dlg4/ PSD95 expression is reduced (e.g. ageing, Alzheimer's disease, Huntington's disease) or increased (e.g. pain disorders) (Arbuckle et al., 2010; Savioz et al., 2014; Zhang et al., 2014; Hong et al., 2016) .
